Literature DB >> 24943220

Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way.

Elisabeth Maier1, Dagmar Werner2, Albert Duschl1, Barbara Bohle3, Jutta Horejs-Hoeck4.   

Abstract

IL-31, a member of the IL-6 protein family, is one of the latest additions to the list of T cell-derived cytokines. Th2 cells are regarded as a main source of IL-31, which is produced in response to stimulation by IL-4. Because the development of Th9 cells also requires IL-4 as a polarizing cytokine, the current study investigates IL-31 production in human Th9 cells compared with Th2 cells. We found that, although Th9 cells were able to release IL-31 during the first weeks of in vitro polarization, no IL-31 was detected in Th9 cultures after a final restimulation in the absence of polarizing cytokines. We further show that TGF-β, which is required to obtain Th9 cells in vitro, potently inhibits the release of IL-31 from Th2 cells, whereas IL-33, a cytokine associated with Th2-mediated inflammation, synergizes with IL-4 in inducing IL-31 secretion. To analyze the molecular mechanisms underlying the induction of IL-31, EMSAs, reporter gene assays, and small interfering RNA-based silencing experiments were carried out. We show that STAT6 and NF-κB are central players in mediating IL-31 expression induced by IL-4/IL-33. In addition, we identified a novel NF-κB-binding element within the Il31 promoter that mediates the enhancing effects of IL-33 on IL-4/STAT6-induced IL-31 expression in human Th2 cells. Taken together, this study shows that IL-4 is essential for the production of IL-31, whereas TGF-β significantly suppresses IL-31 expression at the mRNA and protein levels. As a consequence, in vitro polarized Th2 cells, but not Th9 cells, are able to release IL-31.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24943220      PMCID: PMC4766737          DOI: 10.4049/jimmunol.1301836

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells.

Authors:  Sung-Yun Pai; Morgan L Truitt; I-Cheng Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  PU.1 expression delineates heterogeneity in primary Th2 cells.

Authors:  Hua-Chen Chang; Shangming Zhang; Vivian T Thieu; Roger B Slee; Heather A Bruns; R Nicholas Laribee; Michael J Klemsz; Mark H Kaplan
Journal:  Immunity       Date:  2005-06       Impact factor: 31.745

Review 3.  How diverse--CD4 effector T cells and their functions.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  J Mol Cell Biol       Date:  2009-05-28       Impact factor: 6.216

4.  IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells.

Authors:  Liying Guo; Gang Wei; Jinfang Zhu; Wei Liao; Warren J Leonard; Keji Zhao; William Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-29       Impact factor: 11.205

5.  Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes.

Authors:  Veit J Erpenbeck; Jens M Hohlfeld; Brunhild Volkmann; Andreas Hagenberg; Henning Geldmacher; Armin Braun; Norbert Krug
Journal:  J Allergy Clin Immunol       Date:  2003-06       Impact factor: 10.793

6.  Allergy-associated I epsilon and Ec epsilon receptor II (CD23b) genes activated via binding of an interleukin-4-induced transcription factor to a novel responsive element.

Authors:  I Köhler; E P Rieber
Journal:  Eur J Immunol       Date:  1993-12       Impact factor: 5.532

7.  Human resting CD4+ T cells are constitutively inhibited by TGF beta under steady-state conditions.

Authors:  Sabine Classen; Thomas Zander; Daniela Eggle; Jens M Chemnitz; Benedikt Brors; Ingrid Büchmann; Alexey Popov; Marc Beyer; Roland Eils; Svenja Debey; Joachim L Schultze
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

8.  Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.

Authors:  Alexander U Lüthi; Sean P Cullen; Edel A McNeela; Patrick J Duriez; Inna S Afonina; Clare Sheridan; Gabriela Brumatti; Rebecca C Taylor; Kristof Kersse; Peter Vandenabeele; Ed C Lavelle; Seamus J Martin
Journal:  Immunity       Date:  2009-06-25       Impact factor: 31.745

9.  IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.

Authors:  Valérie Dardalhon; Amit Awasthi; Hyoung Kwon; George Galileos; Wenda Gao; Raymond A Sobel; Meike Mitsdoerffer; Terry B Strom; Wassim Elyaman; I-Cheng Ho; Samia Khoury; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

10.  Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation.

Authors:  Bryony Stott; Paul Lavender; Sarah Lehmann; Davide Pennino; Stephen Durham; Carsten B Schmidt-Weber
Journal:  J Allergy Clin Immunol       Date:  2013-05-18       Impact factor: 10.793

View more
  22 in total

1.  Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression.

Authors:  Ramakrishna Edukulla; Brijendra Singh; Anil G Jegga; Vishwaraj Sontake; Stacey R Dillon; Satish K Madala
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

Review 2.  The continuing evolution of targeted therapy for inflammatory skin disease.

Authors:  C Schlapbach; A A Navarini
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

3.  Long non-coding RNA nuclear paraspeckle assembly transcript 1 promotes activation of T helper 2 cells via inhibiting STAT6 ubiquitination.

Authors:  Shuman Huang; Dong Dong; Yaqian Zhang; Zhuo Chen; Jing Geng; Yulin Zhao
Journal:  Hum Cell       Date:  2021-02-07       Impact factor: 4.174

4.  Commiphora myrrha inhibits itch-associated histamine and IL-31 production in stimulated mast cells.

Authors:  Jae Young Shin; Denis Nchang Che; Byoung Ok Cho; Hyun Ju Kang; Jisu Kim; Seon Il Jang
Journal:  Exp Ther Med       Date:  2019-07-01       Impact factor: 2.447

Review 5.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

6.  Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.

Authors:  Filiberto Cedeno-Laurent; Elisha M Singer; Maria Wysocka; Bernice M Benoit; Carmela C Vittorio; Ellen J Kim; Gil Yosipovitch; Alain H Rook
Journal:  Clin Immunol       Date:  2015-03-08       Impact factor: 3.969

7.  Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment.

Authors:  Alain H Rook; Kathryn A Rook; Daniel J Lewis
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function.

Authors:  Brijendra Singh; Anil G Jegga; Kumar S Shanmukhappa; Ramakrishna Edukulla; Gurjit H Khurana Hershey; Mario Medvedovic; Stacey R Dillon; Satish K Madala
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

9.  EGFR-HIF1α signaling positively regulates the differentiation of IL-9 producing T helper cells.

Authors:  Suyasha Roy; Zaigham Abbas Rizvi; Alexander J Clarke; Felicity Macdonald; Abhaydeep Pandey; Dietmar Martin Werner Zaiss; Anna Kathrina Simon; Amit Awasthi
Journal:  Nat Commun       Date:  2021-06-01       Impact factor: 14.919

10.  Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis.

Authors:  Chul Hwan Bang; Ji Young Song; Yu Mee Song; Ji Hyun Lee; Young Min Park; Jun Young Lee
Journal:  J Clin Med       Date:  2021-05-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.